CRISPR-Cas9 editing of TLR4 to improve the outcome of cardiac cell therapy

[1]  J. Leor,et al.  Osteopontin promotes infarct repair , 2022, Basic Research in Cardiology.

[2]  R. Bassel-Duby,et al.  Toward CRISPR Therapies for Cardiomyopathies , 2021, Circulation.

[3]  A. Brazma,et al.  The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences , 2021, Nucleic Acids Res..

[4]  N. Karrow,et al.  CRISPR-Cas9-mediated knockout of TLR4 modulates Mycobacterium avium ssp. paratuberculosis cell lysate-induced inflammation in bovine mammary epithelial cells. , 2021, Journal of dairy science.

[5]  S. Prabhu,et al.  Cardiac Mesenchymal Stem Cells Promote Fibrosis and Remodeling in Heart Failure , 2021, JACC. Basic to translational science.

[6]  J. Leor,et al.  Extracellular Vesicles From Epicardial Fat Facilitate Atrial Fibrillation , 2021, Circulation.

[7]  P. Doevendans,et al.  Damage-Associated Molecular Patterns in Myocardial Infarction and Heart Transplantation: The Road to Translational Success , 2020, Frontiers in Immunology.

[8]  Nadezhda T. Doncheva,et al.  The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..

[9]  K. Kwiatkowska,et al.  TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling , 2020, Cellular and Molecular Life Sciences.

[10]  R. Bolli,et al.  Administration of cardiac mesenchymal cells modulates innate immunity in the acute phase of myocardial infarction in mice , 2020, Scientific Reports.

[11]  V. Ezenwa,et al.  Complex Tissue Regeneration in Mammals Is Associated With Reduced Inflammatory Cytokines and an Influx of T Cells , 2020, Frontiers in Immunology.

[12]  Yun Wang,et al.  Adipose mesenchymal stem cell-derived extracellular vesicles containing microRNA-26a-5p target TLR4 and protect against diabetic nephropathy , 2020, The Journal of Biological Chemistry.

[13]  Shijun Hu,et al.  The therapeutic potential of mesenchymal stem cells for cardiovascular diseases , 2020, Cell Death & Disease.

[14]  Lei S. Qi,et al.  Therapeutic genome editing in cardiovascular diseases. , 2020, Advanced drug delivery reviews.

[15]  M. Pittenger,et al.  Mesenchymal stem cell perspective: cell biology to clinical progress , 2019, npj Regenerative Medicine.

[16]  J. Molkentin,et al.  An acute immune response underlies the benefit of cardiac stem cell therapy , 2019, Nature.

[17]  F. Spinale,et al.  Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype , 2019, Nature Reviews Cardiology.

[18]  N. Frangogiannis.  How do endosomal Toll-like Receptors (TLRs) sense and extend ischemic myocardial injury? , 2019, Cardiovascular research.

[19]  L. Kirshenbaum,et al.  Inflammation in myocardial injury- mesenchymal stem cells as potential immunomodulators. , 2019, American journal of physiology. Heart and circulatory physiology.

[20]  J. Downey,et al.  Innate immunity as a target for acute cardioprotection. , 2019, Cardiovascular research.

[21]  N. Frangogiannis,et al.  Fibroblasts in the Infarcted, Remodeling, and Failing Heart , 2019, JACC. Basic to translational science.

[22]  D. Funamoto,et al.  Nanoparticle incorporating Toll-like receptor 4 inhibitor attenuates myocardial ischaemia-reperfusion injury by inhibiting monocyte-mediated inflammation in mice. , 2019, Cardiovascular research.

[23]  S. Hoerstrup,et al.  Proteomic analysis of human mesenchymal stromal cell secretomes: a systematic comparison of the angiogenic potential , 2019, npj Regenerative Medicine.

[24]  F. Granucci,et al.  Below the surface: The inner lives of TLR4 and TLR9 , 2019, Journal of leukocyte biology.

[25]  Jing Xu,et al.  Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines , 2018, Journal of Extracellular Vesicles.

[26]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[27]  M. Packer.  The Alchemist’s Nightmare: Might Mesenchymal Stem Cells That Are Recruited to Repair the Injured Heart Be Transformed Into Fibroblasts Rather Than Cardiomyocytes? , 2018, Circulation.

[28]  J. Molkentin,et al.  Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart , 2018, The Journal of clinical investigation.

[29]  X. Cui,et al.  Concise Review: Is Cardiac Cell Therapy Dead? Embarrassing Trial Outcomes and New Directions for the Future , 2018, Stem cells translational medicine.

[30]  Hongliang Li,et al.  Insights into innate immune signalling in controlling cardiac remodelling. , 2017, Cardiovascular research.

[31]  A. Scharenberg,et al.  Therapeutic Gene Editing Safety and Specificity. , 2017, Hematology/oncology clinics of North America.

[32]  M. V. Goncharuk,et al.  Spatial structure of TLR4 transmembrane domain in bicelles provides the insight into the receptor activation mechanism , 2017, Scientific Reports.

[33]  J. Leor,et al.  Left Ventricular Dysfunction Switches Mesenchymal Stromal Cells Toward an Inflammatory Phenotype and Impairs Their Reparative Properties Via Toll-Like Receptor-4 , 2017, Circulation.

[34]  J. Molkentin,et al.  Redefining the identity of cardiac fibroblasts , 2017, Nature Reviews Cardiology.

[35]  Yu-Kyoung Oh,et al.  Therapeutic gene editing: delivery and regulatory perspectives , 2017, Acta Pharmacologica Sinica.

[36]  M. Porteus,et al.  Genome Editing in Cardiovascular Biology , 2017, Circulation research.

[37]  J. Leor,et al.  Loss of Macrophage Wnt Secretion Improves Remodeling and Function After Myocardial Infarction in Mice , 2017, Journal of the American Heart Association.

[38]  R. Califf,et al.  Clarifying Stem-Cell Therapy's Benefits and Risks. , 2016, The New England journal of medicine.

[39]  Yue Tang,et al.  Bone Marrow Mesenchymal Stem Cells (BM-MSCs) Improve Heart Function in Swine Myocardial Infarction Model through Paracrine Effects , 2016, Scientific Reports.

[40]  K. Patel,et al.  Paracrine effects of TLR4-polarised mesenchymal stromal cells are mediated by extracellular vesicles , 2016, Journal of Translational Medicine.

[41]  D. Gattas,et al.  SEPSIS-INDUCED MYOCARDIAL DEPRESSION IS ASSOCIATED WITH APOPTOSIS AND DIFFERENTIAL REGULATION OF S100A1, S100B, AND S100A6 AND THEIR RECEPTORS, RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS AND TOLL-LIKE RECEPTOR 4 , 2015 .

[42]  D. Widera,et al.  Controversial Role of Toll-like Receptor 4 in Adult Stem Cells , 2015, Stem Cell Reviews and Reports.

[43]  Sky W. Brubaker,et al.  Innate immune pattern recognition: a cell biological perspective. , 2015, Annual review of immunology.

[44]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[45]  E. Eggenhofer,et al.  The Life and Fate of Mesenchymal Stem Cells , 2014, Front. Immunol..

[46]  Jae Young Kim,et al.  Anti-CD14 antibody reduces LPS responsiveness via TLR4 internalization in human monocytes. , 2014, Molecular immunology.

[47]  J. Sluijter,et al.  Mesenchymal Stem Cell Therapy for Cardiac Inflammation: Immunomodulatory Properties and the Influence of Toll-Like Receptors , 2013, Mediators of inflammation.

[48]  J. Leor,et al.  Macrophage subpopulations are essential for infarct repair with and without stem cell therapy. , 2013, Journal of the American College of Cardiology.

[49]  W. Fibbe,et al.  Mesenchymal stromal cells: sensors and switchers of inflammation. , 2013, Cell stem cell.

[50]  M. Pevsner-Fischer,et al.  The Origin of Human Mesenchymal Stromal Cells Dictates Their Reparative Properties , 2013, Journal of the American Heart Association.

[51]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[52]  N. Baldini,et al.  Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy , 2012, Front. Physio..

[53]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[54]  N. S. Asli,et al.  Adult cardiac-resident MSC-like stem cells with a proepicardial origin. , 2011, Cell stem cell.

[55]  J. Hare,et al.  Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. , 2011, Circulation research.

[56]  D. Meldrum,et al.  TLR4 Inhibits Mesenchymal Stem Cell (MSC) STAT3 Activation and Thereby Exerts Deleterious Effects on MSC–Mediated Cardioprotection , 2010, PloS one.

[57]  Ruth S. Waterman,et al.  A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype , 2010, PloS one.

[58]  C. Tschöpe,et al.  Toll-Like Receptor-4 Modulates Survival by Induction of Left Ventricular Remodeling after Myocardial Infarction in Mice1 , 2008, The Journal of Immunology.

[59]  M. Goumans,et al.  Toll-Like Receptor 4 Mediates Maladaptive Left Ventricular Remodeling and Impairs Cardiac Function After Myocardial Infarction , 2008, Circulation research.

[60]  L. Cosmi,et al.  Toll‐Like Receptors 3 and 4 Are Expressed by Human Bone Marrow‐Derived Mesenchymal Stem Cells and Can Inhibit Their T‐Cell Modulatory Activity by Impairing Notch Signaling , 2008, Stem cells.

[61]  J. Leor,et al.  Iron-Oxide Labeling and Outcome of Transplanted Mesenchymal Stem Cells in the Infarcted Myocardium , 2007, Circulation.

[62]  C. Liang,et al.  In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro , 2007, Nature Protocols.

[63]  Y. Bae,et al.  Role of Toll‐Like Receptors on Human Adipose‐Derived Stromal Cells , 2006, Stem cells.

[64]  J. Weiss.  Faculty Opinions recommendation of Response of human pulmonary epithelial cells to lipopolysaccharide involves Toll-like receptor 4 (TLR4)-dependent signaling pathways: evidence for an intracellular compartmentalization of TLR4. , 2004 .

[65]  Y. Saga,et al.  Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. , 2003, Cancer research.

[66]  R. Munford,et al.  CD14-dependent internalization of bacterial lipopolysaccharide (LPS) is strongly influenced by LPS aggregation but not by cellular responses to LPS. , 1998, Journal of immunology.